Clinical and molecular aspects of the live attenuated Oka varicella vaccine. - Wikidata - wikimedia - TriplyDB

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

http://www.wikidata.org/entity/Q38200971

about

Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge.Standardization of the methods and reference materials used to assess virus content in varicella vaccines.In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency.Deep Sequencing of Distinct Preparations of the Live Attenuated Varicella-Zoster Virus Vaccine Reveals a Conserved Core of Attenuating Single-Nucleotide Polymorphisms.DNA from Dust: Comparative Genomics of Large DNA Viruses in Field Surveillance Samples Viral forensic genomics reveals the relatedness of classic herpes simplex virus strains KOS, KOS63, and KOS79.A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.Differentiation between wild-type and vaccines strains of varicella zoster virus (VZV) based on four single nucleotide polymorphisms.Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.Fifteen years of routine childhood varicella vaccination in the United States-strong decrease in the burden of varicella disease and no negative effects on the population level thus far.Varicella and herpes zoster vaccine development: lessons learned.A recombinant herpesviral vector containing a near-full-length SIVmac239 genome produces SIV particles and elicits immune responses to all nine SIV gene products.

P2860

Q34991446-9D424895-BC34-4A28-92AE-A8CF0CA8951B Q35816963-EF6DBB7B-A76A-4438-B7A5-B1851469AB52 Q36866120-A1330249-0C16-413D-8FEA-75C8F63AD9EB Q37252950-6E53834D-DF3A-4D33-B92B-D22D59758A62 Q37340086-71926BCB-77E3-482A-AF41-A08F7B8DA44A Q38788289-F15A261D-7513-431F-9433-208F6E2701AE Q40067153-FD988AE7-06E1-4CA6-83DB-6E7185EAC601 Q40106448-6F8837C3-8295-4A29-B00F-25AA8D3BE1BF Q40107328-D195CB01-F5B9-4FDE-9FAA-C8EA91071379 Q41880259-BE7AF41F-42CC-4A1D-936D-3F178526F900 Q47607699-EE1077D3-8A47-4182-9309-2A1A1C0A7665 Q55444789-BB0CA3B9-8356-496B-BAC1-F798F1775CD3

P2860

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

http://www.wikidata.org/entity/Q38200971

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

@en

type

label

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

@en

prefLabel

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

@en

P1433

Q38200971-46567A1D-F0B9-465B-AFAC-17945A27EE78

P1476

Q38200971-686B6697-B6C7-480F-B151-AC14BEAEACAD

P2093

Q38200971-5E51E642-D931-4797-A46F-079101416423

P2860

Q38200971-01CDF368-FF13-45EF-90E3-7BB614DFFDB1

Q38200971-025F33D7-22F6-4D59-AA5D-AC86F012F1FB

Q38200971-02BD9B23-4230-46A2-85AC-48987E4FA1A7

Q38200971-12330FA7-961C-4E9E-B666-6413045359EA

Q38200971-1261B91D-4037-48D5-8E1B-A5C0F51B0094

Q38200971-127979F7-E54A-4EDC-9F94-7A58D8D7E219

Q38200971-184068F2-A766-4A16-9B0C-B090A5C5ADBB

Q38200971-1A9456CE-CF4F-4089-808A-8C6C77458D92

Q38200971-1B2DBD60-7F77-458A-BAFE-7E593DF42DC0

Q38200971-2072430D-5C0B-4F0A-8147-6153979FFC47

P304

Q38200971-EFC03F16-9E00-45AB-8CE1-CDF21077C95B

P31

Q38200971-9EF4958A-E284-4072-9732-93FF6D4F5528

P356

Q38200971-4C576242-0F49-4A5F-909B-D9634A53971E

P433

Q38200971-5A52717A-AC67-4518-BCE4-C4122E2E2215

P478

Q38200971-6CB9A187-6110-4D8F-879B-06C36309C151

P50

Q38200971-ABF02AA2-C4C8-4A49-9735-B0D9F5BFDFC4

P577

Q38200971-BD8E6782-D869-4AE2-9472-300328B1D472

P698

Q38200971-EDC32582-04E0-4984-BAE6-66D064AD46B3

P921

Q38200971-67CBFBEA-463A-49D9-9833-08D48A4F32A6

P356

P1433

Reviews in Medical Virology

P1476

Clinical and molecular aspects of the live attenuated Oka varicella vaccine.

@en

P2093

Mark Quinlivan

http://www.w3.org/2001/XMLSchema#string

P2860

The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003

Case report: occupationally related recurrent varicella (chickenpox) in a hospital nurse.

Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

The safety profile of varicella vaccine: a 10-year review

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells.

Sequencing of 21 varicella-zoster virus genomes reveals two novel genotypes and evidence of recombination

Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo

P304

254-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/RMV.1789

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24687808

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine